Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpuraLinus A. Völker, H Felten, Thomas Osterholt et al.|Journal of Thrombosis and Haemostasis|2023Cited by 50
Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpuraLucas Kühne, Paul Knöbl, Jessica Kaufeld et al.|Journal of Thrombosis and Haemostasis|2022Cited by 30
Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic PurpuraLucas Kühne, Paul T. Brinkkoetter, Dennis A. Eichenauer et al.|Blood|2021Cited by 1